Searchable abstracts of presentations at key conferences on calcified tissues

Bone Abstracts

Published by BioScientifica

Page 24 of about 635 results

ba0005op3 | Clinical | ECTS2016

Vitamin D supplementation for 12 months in older people prevents bone loss and suppresses parathyroid hormone levels

Aspray Terry J , Francis Roger M , McColl Elaine , Chadwick Thomas , Stamp Elaine , Prentice Ann , Schoenmakers Inez

see P221b....
0 shares

ba0005op21 | Clinical (1) | ECTS2016

Impact of 3-year vitamin D and calcium supplementation on mineral and organic matrix formation of trabecular bone in postmenopausal osteoporosis

Paschalis E P , Gamsjaeger S , Hassler N , Fahrleitner-Pammer A , Dobnig H , Stepan J J , Eriksen E F , Klaushofer K

see P407....
0 shares

ba0006oc24 | (1) | ICCBH2017

KRN23 effects on phosphate and vitamin D dysregulation in children <5 years old with X-Linked Hypophosphatemia (XLH)

Imel Erik , Carpenter Thomas , Gottesman Gary S , Martin Javier San , Mao Meng , Skrinar Alison , Whyte Michael P

Objectives: XLH features renal phosphate (Pi) wasting, hypophosphatemia, rickets, and skeletal deformities from elevated circulating levels of fibroblast growth factor 23 (FGF23). KRN23, an investigational fully human monoclonal antibody, binds FGF23 and inhibits its action. Our Phase 2 study of KRN23 in XLH children (ages 5–12 years) is demonstrating improvements in serum Pi and rickets. Here we present our Phase 2 trial evaluating the efficacy and safety of KRN23 in you...
0 shares

ba0001op4 | Clinical | ECTS2013

Relationship between bone mineral density, body composition, skin sclerosis, and serum 25(OH) vitamin D levels in systemic sclerosis

Corrado Addolorata , Neve Anna , Marucci Arcangela , Colia Ripalta , Mele Angiola , Cantatore Francesco Paolo

see PP117....
0 shares

ba0005op20 | Clinical (1) | ECTS2016

Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz therapy among HIV-infected individuals

Hsieh Evelyn , Fraenkel Liana , Han Yang , Xia Weibo , Insogna Karl , Yin Michael , Zhu Ting , Cheng Xinqi , Li Taisheng

see P337....
0 shares

ba0001pp128 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Mass spectrometric immunoassay for intact parathyroid hormone: correlation with immunoassay and application to clinical samples

Couchman L , Taylor D , Krystans B , Lopez M , Prakash A , Sarracino D , Garces A , Vogelsang M , Peterman S , Vadali G , Robinson S , Moniz C

Introduction: Parathyroid hormone (PTH) measurement is of use in i) differential diagnosis of hypercalcaemia and ii) patients with renal impairment at risk of bone disease. PTH immunoassays are complicated by cross-reactivity with truncated (inactive) variant forms, which accumulate in patients with renal impairment. PTH assay variability is a critical governance issue in renal medicine, suggesting an MS-based reference method is required.Aim: To develop...
0 shares

ba0001oc5.4 | Treatment of osteoporosis | ECTS2013

Effects of romosozumab administration on trabecular and cortical bone assessed with quantitative computed tomography and finite element analysis

Graeff C , Campbell G , Pena J , Padhi D , Grossman A , Chang S , Libanati C , Gluer C-C

Romosozumab is an investigational bone-forming agent that inhibits sclerostin. Recent data demonstrated that it stimulated bone formation, decreased bone resorption, and led to rapid and substantial increases in areal bone mineral density (BMD; McClung, J Bone Miner Res 27 (S1) S8–S9, 2012). In a Phase 1b, randomized, double-blind, placebo-controlled, multiple dose study, we studied the effects of romosozumab administered for 3 months and follow-...
0 shares

ba0001ni8 | (1) | ECTS2013

Detection of autoantibodies to osteoprotegerin in patients with rheumatoid arthritis and their association with disease activity

Hauser Barbara , Riches Philip , Gilchrist Tamara , Wilson Jim F , Fraser William D , Ralston Stuart H

see PP383....
1 shares

ba0001op31 | Pre-Clinical | ECTS2013

Adipogenesis occurs at the expense of osteoblast differentiation in primary osteoblasts deficient in protease-activated receptor 2

Kularathna Pamuditha , Pagel Charles N , Hooper John D , Mackie Eleanor J

see PP167....
0 shares

ba0001pp145 | Cancer and bone: basic, translational and clinical | ECTS2013

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

Gobel Andy , Thiele Stefanie , Rauner Martina , Lorenz C Hofbauer , Tilman D Rachner

Introduction: Bone metastases represent a frequent complication of breast cancer and are characterized by increased tumour-driven activation of osteoclasts and subsequent bone loss. Aminobisphosphonates inhibit osteoclast function and are established therapies of skeletal metastases. Similar to statins, they block the mevalonate pathway and are thought to have direct anti-tumour effects. Here, we report on the anti-tumour potential of a sequential inhibition of the mevalonate ...
0 shares

Published by BioScientifica

Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more